

United States Patent and Trademark Office

len

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/796,747	03/09/2004	Dorothca Zucker-Franklin	57953/1201	2516	
7590 12/12/2007 Michael L. Goldman			EXAMINER		
Nixon Peabody	Nixon Peabody LLP			KIM, SUN U	
Clinton Square P.O. Box 31051			ART UNIT	PAPER NUMBER	
Rochester, NY 14603-1051			1797		
			MAIL DATE	DELIVERY MODE	
			12/12/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Office Antion Comme	10/796,747	ZUCKER-FRANKLIN, DOROTHEA			
Office Action Summary	Examiner	Art Unit			
	John Kim	1797			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on 23 Ju	dv 2007				
	☐ This action is FINAL . 2b)☐ This action is non-final.☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1-26</u> is/are pending in the application.					
4a) Of the above claim(s) <u>7-26</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-6</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement				
	election requirement.				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)⊠ The drawing(s) filed on <u>09 March 2004</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). 					
* See the attached detailed Office action for a list of Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	of the certified copies not received 4) Interview Summary (I Paper No(s)/Mail Date 5) Notice of Informal Pail 6) Other:	PTO-413) e			

Application/Control Number: 10/796,747

Art Unit: 1797

1. Claims 7-26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Applicant timely traversed the restriction (election) requirement in the reply filed on 3/28/07.

Page 2

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Meynier, Jr 3. (US Patent No. 2,364,866) in view of Pall et al (US Patent No. 5,229,012) and Arch journal article (Arch Dis Child 2001; 84:381-382 (May)). Meynier, Jr. teaches a nipple shield device comprising a base (2) and a protrusion (4) that is shaped to conform to a mammalian female areola and nipple, wherein the protrusion (4, 8) has one or more holes (9) permitting intake of breast milk by an infant (see figures1-3; col. 1, lines 1-3; col. 1, line 45 - col. 2, line 7). Claims 1-4 essentially differ from the nipple shield device in reciting leukocyte filter or filters attached inside and along the protrusion. Arch journal article teaches that HIV viruses are transmitted to infants via breast feeding and possible removal of virus by filtering (see pages 2-3). Pall et al teach a leukocyte filter of fibrous web or webs (12) contained in a housing (11) via an interference fit (see figure 1; col. 14, lines 41-55; col. 17, lines 28-52; col. 19, lines 13-19). Pall et al further teaches that removal of leukocytes is regarded as beneficial since some viruses including HIV virus are resident in the leukocytes (see col. 1, lines 52-64). It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the nipple shield of Meynier, Jr. to include leukocyte filter of fibrous web or webs in interference fit

Application/Control Number: 10/796,747

Art Unit: 1797

with the inside surface of the nipple shield or along the protrusions to remove leukocytes from breast milk to prevent transmission of HIV viruses to an infant as suggested by Pall et al and Arch journal article.

Regarding claims 5-6, Meynier, Jr. teaches that the nipple shield is made of flexible material including natural rubber, synthetic rubber or the like (see col. 1, lines 45-50).

Applicant's arguments filed 7/23/07 have been fully considered but they are not persuasive.

Applicant argues that Meynier says nothing about filtering at all, let alone filtering leukocytes from breast milk. Applicant argues that Pall et al do not teach or suggest removing leukocytes from breast milk. Arch journal articles or Michie is applied to suggest removal of virus by filtering breast milk (see pages 2-3) wherein Pall et al demonstrate that their filter removes leukocytes which includes HIV viruses (see col. 1, lines 52-64).

Regarding applicant's argument that there is no specific suggestion or teaching in the references to combine prior art, KSR forecloses the argument that a specific teaching, suggestion, or motivation is required to support a finding of obviousness. See the recent Board decision *Ex parte Smith*, --USPQ2d--, slip op. at 20, (Bd. Pat. App. & Interf. June 25, 2007) (citing *KSR*, 82 USPQ2d at 1396).

4. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

Art Unit: 1797

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

- 5. This application contains claims 7-26 drawn to an invention nonelected with traverse in the reply filed on 3/28/07. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John Kim whose telephone number is 571-272-1142. The examiner can normally be reached on Monday-Friday 7 a.m. 3:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Sample can be reached on 571-272-1376. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/John Kim/ Primary Examiner Art Unit 1797

JK 12/9/07